FALSE000154422700015442272020-09-242020-09-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 24, 2020
 
Millendo Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________________
Delaware
 001-35890 45-1472564
(State or Other Jurisdiction of
Incorporation or Organization)
 (Commission File Number)
(I.R.S. Employer
Identification No.)
110 Miller Avenue, Suite 100
Ann Arbor, Michigan
 48104
(Address of Principal Executive Offices)
 (Zip Code)
Registrant’s telephone number, including area code: (734) 845-9000
 
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.001 per share   MLND   The Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 8.01    Other Events.

On September 24, 2020, Millendo Therapeutics, Inc. (the “Company”) issued a press release announcing the dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.

A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.


Item 9.01    Financial Statements and Exhibits.
 
(d)    Exhibits
 
Exhibit
No.		   Description
 
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    MILLENDO THERAPEUTICS, INC.
     
Date: September 24, 2020 By: /s/ Julia C. Owens, Ph.D.
    Julia C. Owens, Ph.D.
    President and Chief Executive Officer